These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33583086)

  • 21. Neuregulin 1 (NRG1) fusion-positive high-grade spindle cell sarcoma: A distinct group of soft tissue tumors with metastatic potential.
    Dermawan JK; Zou Y; Antonescu CR
    Genes Chromosomes Cancer; 2022 Mar; 61(3):123-130. PubMed ID: 34747541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.
    Inoue M; Toki H; Matsui J; Togashi Y; Dobashi A; Fukumura R; Gondo Y; Minowa O; Tanaka N; Mori S; Takeuchi K; Noda T
    Carcinogenesis; 2016 May; 37(5):452-60. PubMed ID: 26964870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring
    Kim DW; Schram AM; Hollebecque A; Nishino K; Macarulla T; Rha SY; Duruisseaux M; Liu SV; Al Hallak MN; Umemoto K; Wesseler C; Cleary JM; Springfeld C; Neuzillet C; Joe A; Jauhari S; Ford J; Goto K
    Future Oncol; 2024; 20(16):1057-1067. PubMed ID: 38348690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities.
    Zhang C; Mei W; Zeng C
    Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188707. PubMed ID: 35247506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers.
    Severson E; Achyut BR; Nesline M; Pabla S; Previs RA; Kannan G; Chenn A; Zhang S; Klein R; Conroy J; Sausen M; Sathyan P; Saini KS; Ghosh A; Jensen TJ; Reddy P; Ramkissoon SH
    J Mol Diagn; 2023 Jul; 25(7):454-466. PubMed ID: 37164276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.
    Chen K; Li W; Xi X; Zhong J
    Thorac Cancer; 2022 Nov; 13(21):3063-3067. PubMed ID: 36096509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1.
    Shin DH; Kim SH; Choi M; Bae YK; Han C; Choi BK; Kim SS; Han JY
    Oncogene; 2022 Jan; 41(2):280-292. PubMed ID: 34743207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
    Odintsov I; Mattar MS; Lui AJW; Offin M; Kurzatkowski C; Delasos L; Khodos I; Asher M; Daly RM; Rekhtman N; de Stanchina E; Ganji G; Ladanyi M; Somwar R
    J Thorac Oncol; 2021 Jul; 16(7):1149-1165. PubMed ID: 33839363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
    Matsuura S; Shinmura K; Kamo T; Igarashi H; Maruyama K; Tajima M; Ogawa H; Tanahashi M; Niwa H; Funai K; Kohno T; Suda T; Sugimura H
    Oncol Rep; 2013 Oct; 30(4):1675-80. PubMed ID: 23877438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Heining C; Horak P; Uhrig S; Codo PL; Klink B; Hutter B; Fröhlich M; Bonekamp D; Richter D; Steiger K; Penzel R; Endris V; Ehrenberg KR; Frank S; Kleinheinz K; Toprak UH; Schlesner M; Mandal R; Schulz L; Lambertz H; Fetscher S; Bitzer M; Malek NP; Horger M; Giese NA; Strobel O; Hackert T; Springfeld C; Feuerbach L; Bergmann F; Schröck E; von Kalle C; Weichert W; Scholl C; Ball CR; Stenzinger A; Brors B; Fröhling S; Glimm H
    Cancer Discov; 2018 Sep; 8(9):1087-1095. PubMed ID: 29802158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements.
    Zhang X; Li L; Gao F; Liu B; Li J; Ren S; Peng S; Qiu W; Pu X; Ye Q
    Diagn Pathol; 2024 Jan; 19(1):1. PubMed ID: 38173003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.
    Nie X; Zhang P; Bie Z; Song C; Zhang M; Ma D; Cui D; Cheng G; Li H; Lei Y; Su X; Wu W; Li L
    World J Surg Oncol; 2023 Aug; 21(1):246. PubMed ID: 37587479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer.
    Umemoto K; Sunakawa Y
    Crit Rev Oncol Hematol; 2021 Oct; 166():103465. PubMed ID: 34454058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
    Nakaoku T; Tsuta K; Ichikawa H; Shiraishi K; Sakamoto H; Enari M; Furuta K; Shimada Y; Ogiwara H; Watanabe S; Nokihara H; Yasuda K; Hiramoto M; Nammo T; Ishigame T; Schetter AJ; Okayama H; Harris CC; Kim YH; Mishima M; Yokota J; Yoshida T; Kohno T
    Clin Cancer Res; 2014 Jun; 20(12):3087-93. PubMed ID: 24727320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NRG1 fusions in breast cancer.
    Howarth KD; Mirza T; Cooke SL; Chin SF; Pole JC; Turro E; Eldridge MD; Garcia RM; Rueda OM; Boursnell C; Abraham JE; Caldas C; Edwards PAW
    Breast Cancer Res; 2021 Jan; 23(1):3. PubMed ID: 33413557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
    Xia H; Xue X; Ding H; Ou Q; Wu X; Nagasaka M; Shao YW; Hu X; Ou SI
    Clin Lung Cancer; 2020 May; 21(3):247-254. PubMed ID: 31761448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
    Davies KD; Le AT; Theodoro MF; Skokan MC; Aisner DL; Berge EM; Terracciano LM; Cappuzzo F; Incarbone M; Roncalli M; Alloisio M; Santoro A; Camidge DR; Varella-Garcia M; Doebele RC
    Clin Cancer Res; 2012 Sep; 18(17):4570-9. PubMed ID: 22919003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.